{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:38:54Z","timestamp":1792607934481,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:37:49Z","timestamp":1664411869000},"page":"1282-1296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Tolerability of Ezetimibe\/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients"],"prefix":"10.1016","volume":"44","author":[{"given":"Juying","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.013_bib0001","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12944-019-1000-0","article-title":"Serum lipid and lipoprotein levels of middle-aged and elderly Chinese men and women in Shandong Province","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0002","first-page":"559","article-title":"Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015","volume":"32","author":"Song","year":"2019","journal-title":"Biomed Environ Sci"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27573","article-title":"Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China","volume":"4","author":"Lu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0004","first-page":"937","article-title":"Guidelines for the prevention and treatment of adult dyslipidemia in China (revised in 2016) (in Chinese)","volume":"31","year":"2016","journal-title":"Chinese Circulation Journal"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0005","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/biomedicines10051090","article-title":"Targeted strategy in lipid-lowering therapy","volume":"10","author":"Dayar","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622316672544","article-title":"Ezetimibe: an update on its clinical usefulness in specific patient groups","volume":"8","author":"Hammersley","year":"2017","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0007","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/ APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0009","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0010","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0011","unstructured":"Haney EM, Huffman LH, Bougatsos C, et\u00a0al. Screening for lipid disorders in children and adolescents. Agency for Healthcare Research and Quality (US); 2007 Jul. Report No.: 07-0598-EF-1. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK33480. Accessed July 28, 2022."},{"key":"10.1016\/j.clinthera.2022.08.013_bib0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0013","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won\u2018t do!","volume":"76","author":"Kr\u00e4henb\u00fchl","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0014","first-page":"4683","article-title":"Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease","volume":"15","author":"Liu","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.clinthera.2021.07.016","article-title":"Effects of fixed-dose combination of low-intensity rosuvastatin and ezetimibe versus moderate-intensity rosuvastatin monotherapy on lipid profiles in patients with hypercholesterolemia: a randomized, double-blind, multicenter, Phase III study","volume":"43","author":"Lee","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0016","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5551\/jat.12013","article-title":"Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin\u2014effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study)","volume":"19","author":"Sasaki","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5551\/jat.40204","article-title":"Statin responses in Chinese patients","volume":"25","author":"Tomlinson","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/0366-6999.149226","article-title":"Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients","volume":"128","author":"Ye","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/FJC.0000000000000914","article-title":"Role of lipid-lowering therapy in low-density lipoprotein cholesterol goal attainment: focus on patients with acute coronary syndrome","volume":"76","author":"Wang","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12944-019-0974-y","article-title":"Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy","volume":"18","author":"Xan","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","article-title":"Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the Dyslipidemia International Study (DYSIS)","volume":"235","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","article-title":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial","volume":"233","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"issue":"suppl_B","key":"10.1016\/j.clinthera.2022.08.013_bib0024","doi-asserted-by":"crossref","first-page":"B47","DOI":"10.1093\/eurheartj\/suv021","volume":"17","author":"Zheng","year":"2015","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jjcc.2013.09.012","article-title":"Preloading with atorvastatin before percutaneous coronary intervention in statin-na\u00efve Asian patients with non-ST elevation acute coronary syndromes: A randomized study","volume":"63","author":"Jang","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0027","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacl.2019.04.011","article-title":"The Statin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy","volume":"13","author":"Jacobson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0028","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/TCRM.S158850","article-title":"Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People\u2018s Republic of China","volume":"14","author":"Li","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcme.2017.06.003","article-title":"Statins use and the risk of liver dysfunction: A Chinese cohort study in real world clinical practice","volume":"16","author":"Gao","year":"2017","journal-title":"IJC Metab Endocr"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0031","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe plus statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1182-5","article-title":"Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature","volume":"19","author":"Yu","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0033","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12944-018-0880-8","article-title":"Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analysis","volume":"17","author":"Ai","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0088","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","volume":"40","author":"Hong","year":"2018","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2022.08.013_bib0034","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12944-018-0909-z","article-title":"Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers","volume":"17","author":"Wu","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0035","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s12325-021-01741-7","article-title":"Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome","volume":"38","author":"Tan","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0036","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12944-015-0004-7","article-title":"Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes","volume":"14","author":"Li","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0037","doi-asserted-by":"crossref","first-page":"467","DOI":"10.23736\/S0392-9590.17.03818-4","article-title":"Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease","volume":"36","author":"Wang","year":"2017","journal-title":"Int Angiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0038","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.curtheres.2012.02.002","article-title":"Clinical efficacy and tolerability of ezetimibe in combination with atorvastatin in Japanese patients with hypercholesterolemia-ezetimibe phase IV randomized controlled trial in patients with hypercholesterolemia","volume":"73","author":"Teramoto","year":"2012","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0039","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-017-0508-4","article-title":"Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects","volume":"16","author":"Sakamoto","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0041","first-page":"578","article-title":"Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease","volume":"32","author":"Luo","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0042","doi-asserted-by":"crossref","first-page":"41","DOI":"10.9734\/jpri\/2021\/v33i21A31367","article-title":"Comparison of efficacy and safety of atorvastatin versus combination of atorvastatin\u2014ezetimibe in newly diagnosed dyslipidemic patients","volume":"33","author":"Philip","year":"2021","journal-title":"J Pharm Res Int"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-511X-13-13","article-title":"Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects \u226565 years","volume":"13","author":"Constance","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0044","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2008.09.075","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease","volume":"102","author":"Conard","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1742-1241.2010.02429.x","article-title":"Incremental cholesterol reduction with ezetimibe\/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets","volume":"64","author":"McCormack","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0046","doi-asserted-by":"crossref","first-page":"41582","DOI":"10.18632\/oncotarget.15078","article-title":"Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0047","first-page":"169","article-title":"The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: a meta-analysis","volume":"20","author":"Zhu","year":"2020","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0048","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1007\/s12325-021-01892-7","article-title":"Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe","volume":"38","author":"Rea","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2022.08.013_bib0049","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","article-title":"Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-C","volume":"111","author":"Katzmann","year":"2022","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:36Z","timestamp":1758963456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002934"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Ezetimibe\/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}